- Home
- BELFB vs ADPT Comparison
BELFB vs ADPT Comparison
Compare BELFB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- ADPT
- Stock Information
- Founded
- BELFB 1949
- ADPT 2009
- Country
- BELFB United States
- ADPT United States
- Employees
- BELFB N/A
- ADPT N/A
- Industry
- BELFB
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BELFB
- ADPT Health Care
- Exchange
- BELFB Nasdaq
- ADPT Nasdaq
- Market Cap
- BELFB 1.0B
- ADPT 929.8M
- IPO Year
- BELFB N/A
- ADPT 2019
- Fundamental
- Price
- BELFB $82.43
- ADPT $7.45
- Analyst Decision
- BELFB Strong Buy
- ADPT Buy
- Analyst Count
- BELFB 3
- ADPT 4
- Target Price
- BELFB $98.33
- ADPT $6.75
- AVG Volume (30 Days)
- BELFB 61.5K
- ADPT 1.3M
- Earning Date
- BELFB 02-19-2025
- ADPT 02-12-2025
- Dividend Yield
- BELFB 0.34%
- ADPT N/A
- EPS Growth
- BELFB N/A
- ADPT N/A
- EPS
- BELFB 4.32
- ADPT N/A
- Revenue
- BELFB $524,943,000.00
- ADPT $177,282,000.00
- Revenue This Year
- BELFB N/A
- ADPT $6.48
- Revenue Next Year
- BELFB $0.77
- ADPT $18.72
- P/E Ratio
- BELFB $18.68
- ADPT N/A
- Revenue Growth
- BELFB N/A
- ADPT N/A
- 52 Week Low
- BELFB $45.75
- ADPT $2.28
- 52 Week High
- BELFB $92.61
- ADPT $7.50
- Technical
- Relative Strength Index (RSI)
- BELFB 54.33
- ADPT 61.48
- Support Level
- BELFB $78.81
- ADPT $5.98
- Resistance Level
- BELFB $80.80
- ADPT $7.28
- Average True Range (ATR)
- BELFB 2.60
- ADPT 0.56
- MACD
- BELFB 0.02
- ADPT 0.04
- Stochastic Oscillator
- BELFB 81.93
- ADPT 96.86
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).